The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era

HIV Med. 2008 Nov;9(10):858-62. doi: 10.1111/j.1468-1293.2008.00629.x. Epub 2008 Aug 21.

Abstract

Objectives: To define the incidence and risk factors for methicillin resistant Staphylococcus aureus (MRSA) bacteraemia in an HIV-infected population.

Methods: From January 1, 2000 to December 31, 2004, we conducted a retrospective cohort study. We identified all cases of Staphylococcus aureus bacteraemia (SAB), including MRSA, among patients enrolled in the Johns Hopkins Hospital out-patient HIV clinic. A conditional logistic regression model was used to identify risk factors for MRSA bacteraemia compared with methicillin-sensitive SAB and no bacteraemia in unmatched (1:1) and matched (1:4) nested case-control analyses, respectively.

Results: Of 4607 patients followed for a total of 11 020 person-years (PY) of follow-up, 216 episodes of SAB occurred (incidence: 19.6 cases per 1000 PY), including 94 cases (43.5%) which were methicillin-resistant. The incidence of MRSA bacteraemia increased from 5.3 per 1000 PY in 2000-2001 to 11.9 per 1000 PY in 2003-2004 (P=0.001). Multivariate analysis demonstrated that independent predictors of MRSA bacteraemia (vs. no bacteraemia) were injection drug use (IDU), end-stage renal disease (ESRD) and CD4 count <200 cells/microL.

Conclusions: MRSA bacteraemia was an increasingly common diagnosis in our HIV-infected cohort, especially in patients with history of IDU, low CD4 cell count and ESRD.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / virology
  • Adult
  • Antiretroviral Therapy, Highly Active*
  • Bacteremia / virology*
  • CD4 Lymphocyte Count
  • Epidemiologic Methods
  • Female
  • HIV Infections / drug therapy*
  • HIV-1*
  • Humans
  • Male
  • Methicillin-Resistant Staphylococcus aureus*
  • Staphylococcal Infections / virology*
  • Viral Load